Share on StockTwits

EXACT Sciences (NASDAQ:EXAS) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 26,442,496 shares, an increase of 4.9% from the July 31st total of 25,198,205 shares, American Banking and Market News reports. Based on an average trading volume of 2,400,773 shares, the short-interest ratio is currently 11.0 days. Approximately 32.4% of the company’s stock are sold short.

A number of research firms have recently commented on EXAS. Analysts at JMP Securities raised their price target on shares of EXACT Sciences from $22.00 to $28.00 in a research note on Wednesday, August 27th. They now have a “market outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $21.00 to $23.00 in a research note on Tuesday, August 26th. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, August 12th. They now have a $20.00 price target on the stock, up previously from $19.00. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $21.00.

Shares of EXACT Sciences (NASDAQ:EXAS) opened at 20.85 on Monday. EXACT Sciences has a 52-week low of $9.53 and a 52-week high of $22.25. The stock’s 50-day moving average is $17.50 and its 200-day moving average is $14.83. The company’s market cap is $1.729 billion.

EXACT Sciences (NASDAQ:EXAS) last released its earnings data on Tuesday, July 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.